Andra AP fonden reduced its position in shares of PerkinElmer, Inc. (NYSE:PKI) by 6.8% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 33,100 shares of the medical research company’s stock after selling 2,400 shares during the quarter. Andra AP fonden’s holdings in PerkinElmer were worth $2,819,000 at the end of the most recent quarter.
A number of other hedge funds have also recently bought and sold shares of PKI. Phocas Financial Corp. acquired a new position in PerkinElmer during the 2nd quarter worth approximately $26,000. Bartlett & Co. LLC raised its stake in PerkinElmer by 430.1% during the 3rd quarter. Bartlett & Co. LLC now owns 493 shares of the medical research company’s stock worth $42,000 after buying an additional 400 shares during the period. Amica Retiree Medical Trust acquired a new position in PerkinElmer during the 2nd quarter worth approximately $48,000. CSat Investment Advisory L.P. raised its stake in PerkinElmer by 74.1% during the 2nd quarter. CSat Investment Advisory L.P. now owns 538 shares of the medical research company’s stock worth $51,000 after buying an additional 229 shares during the period. Finally, Coastal Capital Group Inc. acquired a new position in PerkinElmer during the 2nd quarter worth approximately $58,000. 95.93% of the stock is currently owned by institutional investors and hedge funds.
A number of research analysts recently weighed in on PKI shares. Bank of America raised PerkinElmer from a “neutral” rating to a “buy” rating and set a $105.00 price target on the stock in a research note on Thursday, September 26th. Needham & Company LLC reaffirmed a “hold” rating on shares of PerkinElmer in a research note on Thursday, October 31st. Raymond James reaffirmed an “average” rating and set a $51.00 price target on shares of PerkinElmer in a research note on Tuesday, November 5th. Piper Jaffray Companies downgraded PerkinElmer from an “overweight” rating to a “neutral” rating and dropped their price target for the stock from $104.00 to $89.00 in a research note on Thursday, October 31st. Finally, UBS Group dropped their price target on PerkinElmer from $101.00 to $92.00 and set a “neutral” rating on the stock in a research note on Friday, October 18th. Ten analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $76.61.
Shares of PKI opened at $92.15 on Tuesday. The company has a debt-to-equity ratio of 0.70, a quick ratio of 0.97 and a current ratio of 1.30. The stock has a 50 day moving average price of $87.88 and a two-hundred day moving average price of $88.06. The firm has a market capitalization of $10.32 billion, a P/E ratio of 25.53, a P/E/G ratio of 1.69 and a beta of 1.30. PerkinElmer, Inc. has a 52 week low of $71.83 and a 52 week high of $103.00.
PerkinElmer (NYSE:PKI) last issued its quarterly earnings data on Wednesday, October 30th. The medical research company reported $1.06 EPS for the quarter, topping analysts’ consensus estimates of $1.01 by $0.05. The firm had revenue of $706.92 million during the quarter, compared to analyst estimates of $722.69 million. PerkinElmer had a return on equity of 16.45% and a net margin of 8.27%. The company’s revenue for the quarter was up 4.8% on a year-over-year basis. During the same period in the previous year, the company posted $0.90 EPS. On average, equities analysts forecast that PerkinElmer, Inc. will post 4.08 earnings per share for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, February 7th. Shareholders of record on Friday, January 17th will be issued a dividend of $0.07 per share. This represents a $0.28 dividend on an annualized basis and a yield of 0.30%. The ex-dividend date of this dividend is Thursday, January 16th. PerkinElmer’s dividend payout ratio is currently 7.76%.
In other PerkinElmer news, Director Pascale Witz sold 1,043 shares of the business’s stock in a transaction that occurred on Thursday, November 21st. The stock was sold at an average price of $90.67, for a total transaction of $94,568.81. Following the completion of the sale, the director now directly owns 2,446 shares of the company’s stock, valued at approximately $221,778.82. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 1.80% of the company’s stock.
PerkinElmer, Inc provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. The company operates in two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as laboratory services.
Further Reading: Why do companies engage in swaps?
Want to see what other hedge funds are holding PKI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PerkinElmer, Inc. (NYSE:PKI).
Receive News & Ratings for PerkinElmer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer and related companies with MarketBeat.com's FREE daily email newsletter.